Methylphenidate for fatigue in advanced cancer

A prospective open-label pilot study

Nabeel Sarhill, Declan Walsh, Kristine A. Nelson, Jade Homsi, Susan Legrand, Mellar P. Davis

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Psychostimulants such as methylphenidate are used for fatigue in cancer patients. We report a prospective, open-label, pilot study of the successful use of methylphenidate to treat fatigue in nine of 11 consecutive patients with advanced cancer. Seven had received radiation or chemotherapy, a median of three weeks (range from one to 30 weeks) prior to methylphenidate. A rapid onset of benefit was noted, even in the presence of mild anemia. Sedation and pain also improved in some. Only one patient had side effects severe enough to stop the medication.

Original languageEnglish (US)
Pages (from-to)187-192
Number of pages6
JournalAmerican Journal of Hospice and Palliative Medicine
Volume18
Issue number3
DOIs
StatePublished - Jan 1 2001

Fingerprint

Methylphenidate
Fatigue
Neoplasms
Anemia
Radiation
Drug Therapy
Pain

Keywords

  • cancer
  • fatigue
  • methylphenidate
  • psychostimulant
  • symptom management

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Methylphenidate for fatigue in advanced cancer : A prospective open-label pilot study. / Sarhill, Nabeel; Walsh, Declan; Nelson, Kristine A.; Homsi, Jade; Legrand, Susan; Davis, Mellar P.

In: American Journal of Hospice and Palliative Medicine, Vol. 18, No. 3, 01.01.2001, p. 187-192.

Research output: Contribution to journalArticle

Sarhill, Nabeel ; Walsh, Declan ; Nelson, Kristine A. ; Homsi, Jade ; Legrand, Susan ; Davis, Mellar P. / Methylphenidate for fatigue in advanced cancer : A prospective open-label pilot study. In: American Journal of Hospice and Palliative Medicine. 2001 ; Vol. 18, No. 3. pp. 187-192.
@article{b0edfc54c29f4034a07d34fed232fc22,
title = "Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study",
abstract = "Psychostimulants such as methylphenidate are used for fatigue in cancer patients. We report a prospective, open-label, pilot study of the successful use of methylphenidate to treat fatigue in nine of 11 consecutive patients with advanced cancer. Seven had received radiation or chemotherapy, a median of three weeks (range from one to 30 weeks) prior to methylphenidate. A rapid onset of benefit was noted, even in the presence of mild anemia. Sedation and pain also improved in some. Only one patient had side effects severe enough to stop the medication.",
keywords = "cancer, fatigue, methylphenidate, psychostimulant, symptom management",
author = "Nabeel Sarhill and Declan Walsh and Nelson, {Kristine A.} and Jade Homsi and Susan Legrand and Davis, {Mellar P.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1177/104990910101800310",
language = "English (US)",
volume = "18",
pages = "187--192",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Methylphenidate for fatigue in advanced cancer

T2 - A prospective open-label pilot study

AU - Sarhill, Nabeel

AU - Walsh, Declan

AU - Nelson, Kristine A.

AU - Homsi, Jade

AU - Legrand, Susan

AU - Davis, Mellar P.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Psychostimulants such as methylphenidate are used for fatigue in cancer patients. We report a prospective, open-label, pilot study of the successful use of methylphenidate to treat fatigue in nine of 11 consecutive patients with advanced cancer. Seven had received radiation or chemotherapy, a median of three weeks (range from one to 30 weeks) prior to methylphenidate. A rapid onset of benefit was noted, even in the presence of mild anemia. Sedation and pain also improved in some. Only one patient had side effects severe enough to stop the medication.

AB - Psychostimulants such as methylphenidate are used for fatigue in cancer patients. We report a prospective, open-label, pilot study of the successful use of methylphenidate to treat fatigue in nine of 11 consecutive patients with advanced cancer. Seven had received radiation or chemotherapy, a median of three weeks (range from one to 30 weeks) prior to methylphenidate. A rapid onset of benefit was noted, even in the presence of mild anemia. Sedation and pain also improved in some. Only one patient had side effects severe enough to stop the medication.

KW - cancer

KW - fatigue

KW - methylphenidate

KW - psychostimulant

KW - symptom management

UR - http://www.scopus.com/inward/record.url?scp=0035347910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035347910&partnerID=8YFLogxK

U2 - 10.1177/104990910101800310

DO - 10.1177/104990910101800310

M3 - Article

VL - 18

SP - 187

EP - 192

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 3

ER -